Findlay Park Partners LLP Sells 46,600 Shares of Agilent Technologies, Inc. $A

Findlay Park Partners LLP reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 3.5% during the second quarter, Holdings Channel.com reports. The fund owned 1,287,410 shares of the medical research company’s stock after selling 46,600 shares during the quarter. Agilent Technologies makes up 1.6% of Findlay Park Partners LLP’s investment portfolio, making the stock its 29th biggest position. Findlay Park Partners LLP’s holdings in Agilent Technologies were worth $151,927,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Elevation Point Wealth Partners LLC grew its stake in Agilent Technologies by 15.2% in the second quarter. Elevation Point Wealth Partners LLC now owns 2,124 shares of the medical research company’s stock worth $251,000 after purchasing an additional 281 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Agilent Technologies by 40.2% in the 2nd quarter. Quadrant Capital Group LLC now owns 11,846 shares of the medical research company’s stock worth $1,398,000 after buying an additional 3,395 shares during the period. Vinva Investment Management Ltd grew its position in shares of Agilent Technologies by 35.8% during the 2nd quarter. Vinva Investment Management Ltd now owns 19,466 shares of the medical research company’s stock worth $2,320,000 after buying an additional 5,135 shares in the last quarter. Choreo LLC increased its stake in shares of Agilent Technologies by 2.4% during the second quarter. Choreo LLC now owns 7,114 shares of the medical research company’s stock valued at $840,000 after buying an additional 169 shares during the period. Finally, Northwest & Ethical Investments L.P. raised its holdings in shares of Agilent Technologies by 11.1% in the second quarter. Northwest & Ethical Investments L.P. now owns 428,545 shares of the medical research company’s stock valued at $50,573,000 after acquiring an additional 42,890 shares in the last quarter. Institutional investors own 87.41% of the company’s stock.

Agilent Technologies Stock Performance

Shares of A opened at $154.52 on Thursday. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The firm has a market cap of $43.81 billion, a PE ratio of 36.27, a P/E/G ratio of 4.67 and a beta of 1.29. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $160.27. The stock has a fifty day moving average price of $141.36 and a 200-day moving average price of $126.23.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.01. The company had revenue of $1.86 billion for the quarter, compared to analyst estimates of $1.83 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.46 EPS. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS. Equities research analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 6th will be paid a dividend of $0.255 per share. This represents a $1.02 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Tuesday, January 6th. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.25. Agilent Technologies’s dividend payout ratio (DPR) is currently 23.94%.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 911 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $143.24, for a total transaction of $130,491.64. Following the sale, the chief executive officer directly owned 32,058 shares of the company’s stock, valued at $4,591,987.92. The trade was a 2.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.26% of the company’s stock.

Analysts Set New Price Targets

A has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Agilent Technologies from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Tuesday. TD Cowen lifted their price objective on shares of Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Bank of America upped their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a “neutral” rating in a report on Tuesday. Rothschild Redb upgraded Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Agilent Technologies in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $161.08.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.